Gout News

Healio Rheumatology features the top stories for National Gout Awareness Day, which is held on May 22 by the Gout & Uric Acid Education Society.

An anti-hypertension diet — that emphasizes fruits, vegetables, nuts, legumes, low fat dairy and whole grains and a low intake of sodium, sweetened beverages, and red and processed meats — was linked with a reduced risk for gout, according to a recent analysis. In addition, the Western diet — which contains more red and processed meats, sweetened beverages, desserts, French fries and refined grains — was linked with an increased risk for gout.

DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Svetlana Krasnokutsky, MD, MS, from NYU Langone Medical Center, spoke about an association between osteoarthritis and gout.

DESTIN, Fla. — While often undetected and understudied, pseudogout may be as treatable as rheumatoid arthritis and gout.

Hyperuricemia and hypouricemia were linked with an increased risk for cardiovascular events among patients with gout, according to a recently published study that used electronic medical records data.

All 32 patients who had hyperuricemia associated with gout treated with combination therapy of arhalofenate and febuxostat reached their target serum uric acid level of less than 6 mg/dL, according to results of a recently published study.

In a 5-year average observational period, older age, loop diuretic use and ethnicity were associated with an increased risk for death among patients who had gout for fewer than 10 years.

Ironwood Pharmaceuticals announced the FDA has accepted to review the new drug application for Duzallo, a fixed-dose combination of lesinurad and allopurinol for the treatment of hyperuricemia in patients with uncontrolled gout, according to a press release.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Machelle Manuel, PhD, vice president of medical scientific affairs at Ironwood Pharmaceuticals, reviewed gout research presented at the meeting.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Michael A. Becker, MD, professor emeritus in the Department of Medicine, Section of Rheumatology at the University of Chicago, reviewed his study of lesinurad, a new selective uric reabsorption inhibitor for the treatment of hyperuricemia in patients with gout.